Syngene has announced a strategic collaboration with Johns Hopkins University to advance early‑stage drug discovery programmes and platform technologies emerging from the university’s research labs.
The collaboration will be delivered by SynVent, Syngene's fully integrated drug discovery and development platform that spans discovery biology, medicinal and synthetic chemistry, DMPK (Drug Metabolism and Pharmacokinetics), toxicology and early development.
The pair will also use Syngene’s Connector model, which the company said is designed to bridge high-potential, early-stage assets and technology platforms with strategic investors and downstream partnerships.
Its use will bring together relevant stakeholders to sponsor research and secure licensing options for the resulting intellectual property.
Kenneth Barr, Senior Vice President, Head of Strategic Collaborations, Syngene International, said: "We are delighted to be working with a renowned institution such as Johns Hopkins."
"We are uniquely positioned to translate pioneering research into credible therapeutic candidates and our goal is to significantly compress the time required for high‑potential programmes to become clinically relevant, creating a faster and more efficient pipeline of new medicines."
According to Paul Nkansah, Senior Director of Corporate Partnerships at Johns Hopkins Technology Ventures, this novel collaboration model has the potential to link discoveries from Johns Hopkins laboratories with the drug discovery capabilities of Syngene, pharmaceutical and biotech partners and investors.
Through the collaboration, the pair aim to accelerate groundbreaking innovations developed at Johns Hopkins and turn promising science into credible development programmes that could, ultimately, lead to new options for patients.